Drug Profile
Disulfiram - Ora Bio
Alternative Names: ORA-101; ORA-102Latest Information Update: 19 Dec 2021
Price :
$50
*
At a glance
- Originator Weizmann Institute of Science
- Developer Ora Bio
- Class Antineoplastics; Eye disorder therapies; Small molecules
- Mechanism of Action Angiogenesis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Age-related macular degeneration; Non-small cell lung cancer
Most Recent Events
- 06 Aug 2015 No recent reports of development identified - Phase-II for Age-related macular degeneration (Combination therapy) in Israel (PO)
- 06 Aug 2015 No recent reports of development identified - Phase-II for Non-small cell lung cancer (Combination therapy, First-line therapy) in Israel (PO)
- 23 Mar 2011 ORA 101 is still in phase II trials for Non-small cell lung cancer in Israel